Exco InTouch Unveils Comprehensive White Paper on Effective Mobile Strategies
News Jun 04, 2015
Exco InTouch has announced the release of its latest co-authored White Paper. The authoritative report serves as a comprehensive guide to data capture via mobile electronic clinical outcome assessments (eCOA) and discusses how best to meet the new demands for patient reported outcomes (PRO).
Renowned academic, Brendan Mulhern, of the University of Technology, Sydney, who is currently involved in the development of the EQ-5D-5L value set for England/UK, is a joint author. Furthermore, Prof. Nicholas Bellamy of the University of Queensland, author of the WOMAC and AUSCAN validated indices for Osteoarthritis, has also contributed highly informed comment.
The detailed Paper covers how effective mobile eCOA solutions have the capability to overcome the practical challenges of capturing PRO measures through better quality, reliability, integrity and traceability of the data collected. Moreover, it provides a comprehensive review of the benefits and key considerations that are instrumental to devising a successful mobile strategy for engaging with patients and capturing patient data in clinical trials. This includes designing systems and technology that ensure data privacy, which can accommodate diverse populations and which are globally accessible and tailored enough to meet the needs of patients across multiple geographies. It also covers the best route for incorporating modern validated instruments into mobile data capture.
Privacy is one key area that forms a strong focus of the White Paper, especially the importance of handling patient data safely and securely, in full compliance with regulations, and protecting Personal Identification Information (PII). Additionally, delivering solutions for divergent populations according to their abilities, familiarity with specific mobile and digital technology and their varying demographics, including languages, countries and geographic territories, which is central to any successful strategy, is covered at length.
Tim Davis, CEO of Exco InTouch commented: “The use of mobile technology to interface with patients during clinical trials and to collect their data is well and truly on the rise. Consequently, as leaders in this industry, we decided to take the initiative to work with other industry experts to create this White Paper that we believe will serve as a footprint for how to implement mobile strategies to successfully collect patient data.”
He continued: “The White Paper illustrates how mobile data capture addresses the challenges affecting paper and traditional ePRO methods. It also provides guidance on how to develop strategies that enable the delivery of tailored digital and mobile solutions to large numbers of patients, each with different technological needs and expectations, across an array of different regions, languages and cultures.”
Dr Chris Watson, Product Manager at Exco InTouch commented: “At Exco InTouch, we have long been at the forefront of devising novel strategic approaches that meet the challenges of data capture in clinical studies and we are pleased to share our insights through this medium. From designing mobile solutions for diverse populations, through maintaining data security and privacy to the integration of validated instruments, the White Paper is a valuable resource for anyone seeking to implement an eCOA strategy in their clinical studies”.
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE
£70M Meant for Cancer Drug Development is Reassigned to Prepare for BrexitNews
At the end of last year, the Health Committee held a meeting to discuss Brexit, more specifically the impact this will have on the discovery, development and regulation of medicines, medical devices and biopharmaceuticals.READ MORE